



an Open Access Journal by MDPI

Recent Advances in Gastrointestinal Cancers: From Microbiota Modulation to New Therapeutic Approaches

Guest Editors:

Dr. Serena Martinelli

Department of Experimental and Clinical Medicine, University of Florence, 50139 Florence, Italy

Dr. Elena Niccolai

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Deadline for manuscript submissions:

30 September 2024

Message from the Guest Editors

We are interested in:

- Modulation of the microbiota: role of the gut microbiome in influencing GI cancer development and response to treatment; manipulation of the microbiota through interventions such as probiotics, prebiotics, and fecal microbiota transplantation; and methods of modulating the microbiome to enhance response to immunotherapies, such as checkpoint inhibitors.
- Immunotherapy: efficacy of checkpoint inhibitors, such as pembrolizumab and nivolumab, in various GI malignancies and the exploration of CAR-T potential in GI cancers.
- Precision medicine: advances in molecular profiling and genomics, leading to the identification of specific biomarkers associated with GI cancers, and the development of liquid biopsy techniques for monitoring GI cancers.
- Targeted therapies: identify additional targeted therapies for specific subtypes of GI cancers in addition to HER2 therapies.
- Artificial intelligence in diagnostics: evaluation of machine learning algorithms to analyze medical images and to predict the prognosis and disease outcomes of GI cancers.



mdpi.com/si/203394

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)